Analysis of complications of giant gastric ulcers induced by hepatic arterial infusion chemotherapy or combined immunotherapy: A report of three cases

Chen,Sheng; Zhao,Nan; Li,Xiangrong; Cao,Dedong

doi:10.3892/etm.2024.12707

Analysis of complications of giant gastric ulcers induced by hepatic arterial infusion chemotherapy or combined immunotherapy: A report of three cases

Authors:
- Sheng Chen
- Nan Zhao
- Xiangrong Li
- Dedong Cao
View Affiliations

Affiliations: Department of Oncology, Xiaogan Hospital Affiliated to Wuhan University of Science and Technology, Xiaogan, Hubei 432000, P.R. China, Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430000, P.R. China
Published online on: September 6, 2024 https://doi.org/10.3892/etm.2024.12707
Article Number: 418
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Primary liver cancer is a major public health issue in China, with high incidence and mortality rates. Notably, progress has been made in improving the surgical methods and hepatic arterial infusion chemotherapy (HAIC) regimens of liver cancer and the combination of HAIC with immunotherapy is expected to further increase the surgical conversion rate or objective response rate. However, patients with liver cancer often have underlying cirrhosis, which may lead to complications, such as esophageal varices and high‑pressure gastric diseases. The present study describes three cases of giant gastric ulcers that occurred during the process of HAIC or combined immunotherapy. Notably, the causal relationship between HAIC and immunotherapy is unclear. In patients with tumors receiving immunotherapy, gastrointestinal adverse reactions are common, and some may develop serious complications, such as gastrointestinal perforation. The present study provides a detailed analysis of this issue and emphasizes the need for further clarification of its mechanisms and effective treatment methods.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.PubMed/NCBI View Article : Google Scholar
2	Chen W, Zheng R, Zeng H and Zhang S: The incidence and mortality of major cancers in China, 2012. Chin J Cancer. 35(73)2016.PubMed/NCBI View Article : Google Scholar
3	He MK, Le Y, Li QJ, Yu ZS, Li SH, Wei W, Guo RP and Shi M: Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: A prospective non-randomized study. Chin J Cancer. 36(83)2017.PubMed/NCBI View Article : Google Scholar
4	Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, Yang TS, Bhudhisawasdi V, Kang WK, Zhou Y, et al: Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol. 31:3501–3508. 2013.PubMed/NCBI View Article : Google Scholar
5	Shao YY, Huang CC, Liang PC and Lin ZZ: Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma. Asia Pac J Clin Oncol. 6:80–88. 2010.PubMed/NCBI View Article : Google Scholar
6	Li QJ, He MK, Chen HW, Fang WQ, Zhou YM, Xu L, Wei W, Zhang YJ, Guo Y, Guo RP, et al: Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: A Randomized phase III trial. J Clin Oncol. 40:150–160. 2022.PubMed/NCBI View Article : Google Scholar
7	He MK, Liang RB, Zhao Y, Xu YJ, Chen HW, Zhou YM, Lai ZC, Xu L, Wei W, Zhang YJ, et al: Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma. Ther Adv Med Oncol. 13(17588359211002720)2021.PubMed/NCBI View Article : Google Scholar
8	Mai Q, Mo Z, Shi F and Chen X: Lenvatinib plus hepatic arterial infusion of modified FOLFOX regime in patients with advanced hepatocellular carcinoma. J Clin Oncol. 38 (Suppl 15):2020.
9	Gu YK, Zhang TQ, Huang ZL, Geng ZJ, Chen C, LI FG, Xu L, Sun J, LI J, Huang ZM and Shen L: Hepatic artery infusion chemotherapy combined with apatinib and toripalimab in advanced hepatocellular carcinoma: Real-world data from a single center. J Clin Oncol. 38 (Suppl 15)(e16602)2020.
10	Qin S, Chen Z, Liu Y, Xiong J, Ren Z, Meng Z, Gu S, Wang L and Zou J: A phase II study of anti-PD1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for advanced hepatocellular carcinoma or biliary tract cancer. J Clini Oncol. 37 (Suppl 15)(4074)2019.
11	Liu BJ, Gao S, Zhu X, Guo JH, Kou FX, Liu SX, Zhang X, Wang XD, Cao G, Chen H, et al: Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma. Immunotherapy. 13:1395–1405. 2021.PubMed/NCBI View Article : Google Scholar
12	Gupta A, De Felice KM, Loftus EV Jr and Khanna S: Systematic review: Colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther. 42:406–417. 2015.PubMed/NCBI View Article : Google Scholar
13	Dougan M: Gastrointestinal and hepatic complications of immunotherapy: Current management and future perspectives. Curr Gastroenterol Rep. 22(15)2020.PubMed/NCBI View Article : Google Scholar
14	Sugiyama Y, Tanabe H, Matsuya T, Kobayashi Y, Murakami Y, Sasaki T, Kunogi T, Takahashi K, Ando K, Ueno N, et al: Severe immune checkpoint inhibitor-associated gastritis: A case series and literature review. Endosc Int Open. 10:E982–E989. 2022.PubMed/NCBI View Article : Google Scholar
15	Anteby R, Kemeny NE, Kingham TP, D'Angelica MI, Wei AC, Balachandran VP, Drebin JA, Brennan MF, Blumgart LH and Jarnagin WR: Getting chemotherapy directly to the liver: The historical evolution of hepatic artery chemotherapy. J Am Coll Surg. 232:332–338. 2021.PubMed/NCBI View Article : Google Scholar
16	Doria MI Jr, Doria LK, Faintuch J and Levin B: Gastric mucosal injury after hepatic arterial infusion chemotherapy with floxuridine. A clinical and pathologic study. Cancer. 73:2042–2047. 1994.PubMed/NCBI View Article : Google Scholar
17	Suzuki H and Ishii H: Peptic ulcer disease complicated with liver cirrhosis. Nihon Rinsho. 62:532–540. 2004.PubMed/NCBI(In Japanese).
18	Hu J, Cao G, Xu L, Zheng K, Zhu X, Yang R and Wang X and Wang X: Retrograde embolization technique of the right gastric artery during the implantation of port-catheter system for hepatic arterial infusion chemotherapy. J Interv Med. 4:27–31. 2020.PubMed/NCBI View Article : Google Scholar
19	Yamagami T, Arai Y, Matsueda K, Inaba Y, Sueyoshi S and Takeuchi Y: The cause of nontumorous defects of portal perfusion in the hepatic hilum revealed by CT during arterial portography. AJR Am J Roentgenol. 172:397–402. 1999.PubMed/NCBI View Article : Google Scholar
20	Imamine R, Shibata T, Shinozuka K and Togashi K: Complications in hepatic arterial infusion chemotherapy: Retrospective comparison of catheter tip placement in the right/left hepatic artery vs. the gastroduodenal artery. Surg Today. 47:851–858. 2017.PubMed/NCBI View Article : Google Scholar
21	Gonzalez RS, Salaria SN, Bohannon CD, Huber AR, Feely MM and Shi C: PD-1 inhibitor gastroenterocolitis: Case series and appraisal of ‘immunomodulatory gastroenterocolitis’. Histopathology. 70:558–567. 2017.PubMed/NCBI View Article : Google Scholar
22	Ai Q, Chen W, Li Y and Li G: Upper Gastrointestinal Tract IrAEs: A case report about sintilimab-induced acute erosive hemorrhagic gastritis. Front Immunol. 13(840916)2022.PubMed/NCBI View Article : Google Scholar
23	Kobayashi M, Yamaguchi O, Nagata K, Nonaka K and Ryozawa S: Acute hemorrhagic gastritis after nivolumab treatment. Gastrointest Endosc. 86:915–916. 2017.PubMed/NCBI View Article : Google Scholar
24	Onuki T, Morita E, Sakamoto N, Nagai Y, Sata M and Hagiwara K: Severe upper gastrointestinal disorders in pembrolizumab-treated non-small cell lung cancer patient. Respirol Case Rep. 6(e00334)2018.PubMed/NCBI View Article : Google Scholar
25	Zhang ML, Neyaz A, Patil D, Chen J, Dougan M and Deshpande V: Immune-related adverse events in the gastrointestinal tract: Diagnostic utility of upper gastrointestinal biopsies. Histopathology. 76:233–243. 2020.PubMed/NCBI View Article : Google Scholar
26	Patil PA and Zhang X: Pathologic manifestations of gastrointestinal and hepatobiliary injury in immune checkpoint inhibitor therapy. Arch Pathol Lab Med. 145:571–582. 2021.PubMed/NCBI View Article : Google Scholar
27	Chen JH, Pezhouh MK, Lauwers GY and Masia R: Histopathologic features of colitis due to immunotherapy with anti-PD-1 antibodies. Am J Surg Pathol. 41:643–654. 2017.PubMed/NCBI View Article : Google Scholar